Out of 4 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Synergy Pharmaceuticals has been the topic of 7 analyst reports since October 1, 2015 according to StockzIntelligence Inc. Rodman & Renshaw maintained the stock on May 9 with “Buy” rating. Below is a list of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) latest ratings and price target changes.
09/05/2016 Broker: Rodman & Renshaw Rating: Buy Old Target: $16.00 New Target: $15.00 Maintain
21/03/2016 Broker: Rodman & Renshaw Rating: Buy Old Target: $17.00 New Target: $16.00 Maintain
16/03/2016 Broker: Citigroup Rating: Neutral Old Target: $7.00 New Target: $4.00 Maintain
About 1.44 million shares traded hands. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 52.27% since February 8, 2016 and is uptrending. It has outperformed by 35.78% the S&P500.
Synergy Pharmaceuticals Inc. is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal (GI) therapies. The company has a market cap of $909.07 million. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It currently has negative earnings. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
The institutional sentiment increased to 1.61 in 2016 Q2. Its up 0.55, from 1.06 in 2016Q1. The ratio is positive, as 16 funds sold all Synergy Pharmaceuticals Inc shares owned while 28 reduced positions. 25 funds bought stakes while 46 increased positions. They now own 99.69 million shares or 58.37% more from 62.94 million shares in 2016Q1.
Great Point Partners Llc holds 8.26% of its portfolio in Synergy Pharmaceuticals Inc for 7.59 million shares. Armistice Capital Llc owns 1.33 million shares or 1.92% of their US portfolio. Moreover, Belmont Global Advisors Inc. has 1.4% invested in the company for 385,000 shares. The New York-based Trellus Management Company Llc has invested 1.01% in the stock. Dafna Capital Management Llc, a California-based fund reported 319,563 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.